Targeted antibody may boost brain cancer treatment after incomplete surgery

NCT ID NCT07707973

Not yet recruiting Disease control Sponsor: Tianjin First Central Hospital Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding nimotuzumab—an antibody that blocks a protein called EGFR—to the standard Stupp regimen (temozolomide plus radiotherapy) can improve outcomes for adults with glioblastoma that was not fully removed by surgery. Participants must have EGFR-positive tumors and measurable residual disease. The study measures progression-free survival, overall survival, and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nimotuzumab, an experimental antibody that targets EGFR, combined with standard temozolomide chemotherapy and radiotherapy
What this could lead to: If successful, this combination could offer a new standard treatment option for people with EGFR-positive glioblastoma that was not fully removed by surgery.
What could go wrong: This is a small, single-arm phase 2 study, so results may not be definitive. The drug may cause side effects like infusion reactions or fatigue, and it may not improve survival compared to current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA, MALIGNANT

More trials for these conditions

Other studies related to the condition(s) this trial covers.